DF Deutsche Forfait Aktie 32859959 / DE000A2AA204
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
30.09.2025 11:27:04
|
EQS-News: Half-year report 2025 published
|
EQS-News: DF Deutsche Forfait AG
/ Key word(s): Half Year Report
Cologne, 30 September 2025 – DF Deutsche Forfait AG (ISIN: DE000A2AA204) (DF AG) published its half-year report 2025 today. The core business in the ‘Trade Finance’ segment continues to develop positively. Business volume rose to EUR 118.1 million in the first half of 2025 (previous year: EUR 105.1 million), exceeding expectations with an increase of around 12%. Gross profit, generated primarily from trade finance, also increased by around 23% to EUR 5.8 million (previous year: EUR 4.7 million). Earnings before taxes (EBT) amounted to EUR 1.1 million in the first half of 2025, significantly below the previous year's figure of EUR 2.0 million. This was primarily due to the significant increase in personnel costs as a result of the acquisitions of DF Vagabund and DF Blutplasma as of the reporting date, as well as additional investments and start-up costs for the establishment of these new segments. Consolidated earnings for the first half of 2025 amounted to EUR 0.4 million or EUR 0.04 per share (previous year: EUR 1.5 million or EUR 0.12 per share). DF AG's cash and cash equivalents totalled EUR 31.1 million as of 30 June 2025 and additionally EUR 7.0 million from other current assets. ‘The first half of 2025 was marked by investments in the DF Vagabund in Berlin and the acquisition of the assets of a blood plasma company in Bochum,’ explains CEO Dr Behrooz Abdolvand. ‘This has enabled us to further diversify our expertise in the food & beverage and health & pharmaceuticals sectors, and we are well on track to generate positive returns from these business areas in the medium term. Although the geopolitical changes in the Middle East have no direct impact on our existing business, they do affect the way we conduct our business. At the same time, we are broadening our base in order to develop new business outside our existing target markets.’ The auditors have issued a report on their audit review. As already reported in the ad hoc announcement of 26 September 2025, the Management Board expects a slight increase in business volume of between 5% and 10% for the current financial year 2025. At the same time, gross profit is still expected to increase by 15% to 25% and earnings before taxes to decline by around 50%. The half-year report is available on our website at https://www.dfag.de/en/investor-relations/publications/ About DF Group The DF Group is a listed financial and investment company with business divisions in trade finance, food & beverage, and health & pharma. In its core business of foreign trade financing, the DF Group has decades of experience, a strong international network, and proven compliance expertise with a regional focus on the Middle East, Europe, and Central Asia. With its investments in the food & beverage and health & pharma sectors, the DF Group is consistently expanding its diversification strategy and developing new sources of income in high-growth industries. M&A activities are also an integral part of the business model. Contact DF Deutsche Forfait AG Guido Janzen
30.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | DF Deutsche Forfait AG |
| Gustav-Heinemann-Ufer 56 | |
| 50968 Köln | |
| Germany | |
| Phone: | +49 221 97376 - 0 |
| E-mail: | dfag@dfag.de |
| Internet: | www.dfag.de |
| ISIN: | DE000A2AA204, DE000A1R1CC4, |
| WKN: | A2AA20, A1R1CC |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2205970 |
| End of News | EQS News Service |
|
|
2205970 30.09.2025 CET/CEST
Nachrichten zu DF Deutsche Forfait AG
Analysen zu DF Deutsche Forfait AG
Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer
Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉
Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.
💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI geht wenig bewegt ins Wochenende -- DAX schliesslich mit Abgaben -- Wall Street beenden Handel uneins -- Asiens Börsen letztlich schwächerDer heimische Aktienmarkt tendierte am Freitag seitwärts, während der deutsche Aktienmarkt sich abwärts bewegte. An der Wall Street ging es am Freitag in unterschiedliche Richtungen. An den Märkten in Fernost ging es zum Wochenende nach unten.


